Barclays’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-433
| Closed | – | – | 5632 |
|
|
2022
Q3 | $0 | Sell |
433
-6,000
| -93% | -$5.54K | ﹤0.01% | 5377 |
|
|
2022
Q2 | $7K | Buy |
6,433
+4,000
| +164% | +$6.6K | ﹤0.01% | 4740 |
|
|
2022
Q1 | $12K | Hold |
2,433
| – | – | ﹤0.01% | 4580 |
|
|
2021
Q4 | $13K | Sell |
2,433
-691
| -22% | -$5.87K | ﹤0.01% | 3982 |
|
|
2021
Q3 | $34K | Buy |
3,124
+105
| +3% | +$1.32K | ﹤0.01% | 4228 |
|
|
2021
Q2 | $52K | Sell |
3,019
-3,262
| -52% | -$61.8K | ﹤0.01% | 4118 |
|
|
2021
Q1 | $166K | Buy |
6,281
+2,624
| +72% | +$119K | ﹤0.01% | 3798 |
|
|
2020
Q4 | $131K | Sell |
3,657
-2,099
| -36% | -$75.9K | ﹤0.01% | 4005 |
|
|
2020
Q3 | $203K | Buy |
5,756
+627
| +12% | +$27.3K | ﹤0.01% | 3840 |
|
|
2020
Q2 | $217K | Buy |
5,129
+4,816
| +1,539% | +$325K | ﹤0.01% | 4003 |
|
|
2020
Q1 | $25K | Sell |
313
-630
| -67% | -$50.4K | ﹤0.01% | 5569 |
|
|
2019
Q4 | $87K | Buy |
943
+477
| +102% | +$40.2K | ﹤0.01% | 5544 |
|
|
2019
Q3 | $35K | Sell |
466
-142
| -23% | -$10.9K | ﹤0.01% | 6064 |
|
|
2019
Q2 | $61K | Buy |
+608
| New | +$47.1K | ﹤0.01% | 6005 |
|
Barclays's EVFM Position: Q4 2022 in Review
Barclays sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2022, closing a stake of 433 shares.
Barclays first reported a position in EVFM in Q2 2019 and held it in 14 quarters. The position peaked at $217K in Q2 2020. 0 funds tracked by Wall St. Rank hold EVFM as of Q4 2022.
- Barclays reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Barclays sold 433 Evofem Biosciences, Inc. Common Stock shares in Q4 2022.
- Barclays first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2019 and held it in 14 quarters.
- Barclays's Evofem Biosciences, Inc. Common Stock position peaked at $217K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2022.
Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.